Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Unbiased identification of nanoparticle cell uptake mechanism via a genome-wide CRISPR/Cas9 knockout screen

ABSTRACT: A major bottleneck in nanocarrier and macromolecule development for therapeutic delivery is our limited understanding of the processes involved in their uptake into target cells. This includes their active interactions with membrane transporters that co-ordinate cellular uptake and processing. Current strategies to elucidate the mechanism of uptake, such as painstaking manipulation of individual effectors with pharmacological inhibitors or specific genetic knockdowns, are limited in scope and biased towards previously studied pathways or the intuition of the investigators. Furthermore, each of these approaches present significant off-target effects, clouding the outcomes. We set out to demonstrate that an unbiased whole-genome screening approach using pooled CRISPR/Cas9 libraries can provide a robust and rapid approach to identify novel effectors of material uptake. We develop a methodology termed fast-library of inserts (FLI)-seq for library preparation and quantitative readout of pooled screens that shows improved technical reproducibility and is easier to perform than existing methods. In this proof-of-concept study we use this approach FLI-seq to identify a solute carrier protein family member SLC18B1 as a candidate transporter for polymeric micelles.

ORGANISM(S): Homo sapiens

PROVIDER: GSE157524 | GEO | 2025/08/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcription profiling of human Ewing sarcoma (A673) cells treated with cytarabine, doxorubicin and puromycin oral tongue squamous cell carcinomas to identify novel potential prognosticators

Project description:An increasing number of cancer-associated mutations have been identified. Unfortunately, little therapy today exploits these tumor-specific genetic lesions. Often, the resulting oncoproteins have been intractable to easy manipulation with current small molecule screening approaches. To overcome this impasse, we developed an expression-based approach to small molecule library screening. We applied this platform to the discovery of modulators of the activity of EWS/FLI, the Ewing sarcoma associated oncoprotein. Cytarabine (ARA-C) was identified as the top hit in a small molecule library screen. ARA-C modulates EWS/FLI by decreasing EWS/FLI protein level and has striking effects on cellular viability and transformation in in vitro and in vivo models of Ewing sarcoma. With poor outcomes for patients with relapsed Ewing sarcoma and the well established safety profile of ARA-C, clinical trials testing ARA-C in Ewing sarcoma are warranted. Expression data was created for A673 cells treated with ARA-C and two other compounds used to treat Ewing sarcoma (Puromycin and Doxorubicin) at two doses (EC50 and 2xEC50) and three time points (24 hours, 3 days, and 5 days). Experiment Overall Design: A673 cells were treated with ARA-C (at doses of EC50 and 2xEC50) or vehicle in triplicate and expression profiled at 24 hours, 3 days, and 5 days. To exclude the possibility that ARA-C's modulation of the EWS/FLI signature was simply a non-specific response to treatment with all cytotoxic agents, we asked whether other compounds known to kill Ewing sarcoma cells (Doxorubicin and Puromycin) would induce the EWS/FLI off genome-wide expression pattern. A673 cells were treated with Doxorubicin and Puromycin (at doses of EC50 and 2xEC50) and expression profiled at 24 hours, 3 days, and 5 days.

2008-11-22 | E-GEOD-6930 | biostudies-arrayexpress

Expression data from A673 cell line treated with compounds at several doses and time points

2007-03-01 | GSE6930 | GEO

Synergistic Stromal Remodeling and Dual Chemo-Immunotherapy in Pancreatic Cancer: A Two-Stage Losartan-Primed followed Nanocarrier Strategy for Tumor Microenvironment Reprogramming

Project description:Pancreatic ductal adenocarcinoma (PDAC) is marked by a dense, fibrotic stroma that hinders drug delivery and promotes an immunosuppressive microenvironment. We developed a two-stage therapeutic strategy (LIGEL) that combines losartan-mediated stromal preconditioning with the targeted delivery of a hybrid nanocarrier (IGEL) co-loaded with gemcitabine and IL-12 circRNA. The efficacy of this approach was evaluated in vitro and in vivo, with RNA sequencing used to explore transcriptomic changes in the tumor microenvironment after treatment. Losartan pretreatment significantly reduced extracellular matrix deposition and cancer-associated fibroblast activation, enhancing cellular uptake and tumor penetration. This resulted in notable tumor growth inhibition, prolonged survival, and minimized gemcitabine-associated systemic toxicity. Transcriptomic analysis revealed tumor cell depletion and immune microenvironment activation. These findings highlight the potential of losartan-primed nanotherapy to reprogram the tumor microenvironment and improve the efficacy of combined chemotherapy-immunotherapy.

2025-12-31 | GSE306986 | GEO

Human A673 Ewing sarcoma secretome - effect of EWS-FLI-1 silencing

Project description:EWS-FLI-1 was silenced by an shRNA in A673 Ewing sarcoma cells and the resulting alterations in the secretome was analyzed by GeLC-MS/MS approach (six gel slices for each sample, luciferase shRNA-expressing cell secretome as control)

2021-07-06 | PXD016052 | Pride

Modification of miRNA profile in Caco-2 cells by dietary lipids

Project description:The aim of this study was to detect miRNAs modified by biactive dietary lipids in a cellular model of enterocytes. The selected model was Caco-2 cells Differentiated Caco-2 cells were incubated with micelles containing the lipids for 24 and 48 hours. The expression leveles of the miRNAs were compared with cells treated with empty micelles. Four control and choelsterol samples, three DHA samples and two CLA samples were analyzed variables: Control (Empty micelles), Cholesterol 250 M-BM-5M 48h, DHA 200 M-BM-5M 24h, CLA 200M-BM-5M 24h Biological replicates Control: Samples 137, 159, 160, 210 Cholesterol: Samples 150, 151, 152, 219 DHA: Samples 141, 142, 143 CLA: Samples 144, 146

2015-03-01 | E-GEOD-59153 | biostudies-arrayexpress

Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning

Project description:Efficient and accurate nanocarrier development for targeted drug delivery is hindered by the inability to analyze cell-level biodistribution across intact whole organisms. We introduce SCP-Nano (Single Cell Precision Nanocarrier Identification), a deep learning pipeline designed to quantify the targeting of millions of cells by nanocarriers in whole-mouse bodies imaged at cellular resolution. SCP-Nano revealed the tissue distribution patterns of lipid nanoparticles (LNPs) following different injection routes at doses as low as 0.0005 mg/kg—far below the detection limits of conventional whole-body imaging techniques. Notably, we demonstrated that LNPs carrying SARS-CoV-2 spike mRNA reach heart tissue, leading to changes in the heart's protein composition that suggest immune activation and possible blood vessel damage. Additionally, we showed that SCP-Nano can analyze various types of nanocarriers, including liposomes, polyplexes, DNA origami, and adeno-associated viruses (AAVs). SCP-Nano's high sensitivity enables accurate 3D mapping of nanocarrier distribution throughout mouse bodies, even detecting very low levels in unexpected tissues. SCP-Nano is poised to accelerate the development of precise and safe nanocarrier-based therapeutics.

2024-12-06 | PXD056871 | Pride

Bile acids regulate lipid metabolism through selective actions on fatty acid absorption

Project description:Intestinal lipid absorption, the entry-point for fats into the body, requires the coordinated actions of bile acids and lipases. Here, we uncover distinct yet cooperative roles of bile acids in driving the differential uptake of dietary fatty acids. We first decreased bile acid pool size by disrupting the rate-limiting enzyme in bile acid synthesis, Cyp7a1, using liver-directed gene editing in mice. Compared to lipase inhibition, reduced bile acids prevented diet-induced obesity, increased anorectic hormones, suppressed excessive eating, and improved systemic lipid metabolism. Remarkably, decreasing bile acids selectively decreased absorption of saturated fatty acids, but preserved polyunsaturated fatty acids. By targeting additional bile acid enzymes, we identified specific functions of individual bile acid species. Mechanistically, we show that cholic acid preferentially solubilizes polyunsaturated fatty acids into mixed micelles for intestinal uptake. Our studies demonstrate that bile acids can selectively control fatty acid uptake, revealing insights for future interventions in metabolic disease.

2025-11-17 | GSE304800 | GEO

DDA-MS serum proteomics in dogs with leishmaniosis

Project description:Serum proteomes of healthy and Leishmania-infected dogs were analyzed by DDA-MS approach to generate sample-specific spectral library for subsequent SWATH-MS analysis, namely pooled, mixed control, mixed case (Leishmania-infected), ProteoMiner enriched, and 3 SCX fractions; all containing iRT peptides for retention time normalization.

2023-05-10 | PXD039763 | Pride

Intranasal administration of a multiplex targeting SCLMs@FEN1-hpDNAs with synergistic baicalein for pulmonary anti-viral treatment

Project description:Here we reported an anti-viral strategy for SARS-CoV-2 infection: intranasal administration of silica cross-linked micelles (SCLMs) encapsulating in vitro purified NES-FEN1-NES protein and a set of hpDNAs (shorted as SCLMs@FEN1-hpDNAs). The set of hpDNAs multiplex targeted SARS-CoV-2’s N gene RNA and the host Ctsl gene mRNA. In vitro experiments demonstrated the purified NES-FEN1-NES protein transfected into cells has efficient mRNA knockdown ability when guided by hpDNAs. The intranasal administration of SCLMs exhibited high pulmonary accessibility, and SCLMs@FEN1-hpDNAs effectively downregulated targeted gene expression in vivo. The efficacy is enhanced by synergistic intranasal baicalein by improving cellular uptake and anti-inflammatory effects. In a mouse model of SARS-CoV-2 infection, the combination with baicalein and SCLMs@FEN1-hpDNAs inhibited the virus replication, improved survival rates, and reduced neuroinflammation. This study highlights the potential of intranasal SCLMs@FEN1-hpDNAs with baicalein as a promising approach for treating respiratory diseases.

2024-12-19 | GSE284624 | GEO

Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription

Project description:Using EWS-FLI and its parental transcription factor, FLI1, we created a unique experimental system to address questions regarding the genomic mechanisms by which chimeric transcription factors cause cancer. We found that in tumor cells, EWS-FLI targets regions of the genome distinct from FLI1, despite identical DNA-binding domains. In primary endothelial cells, however, EWS-FLI and FLI1 demonstrate similar targeting. To understand this mistargeting, we examined chromatin organization. Regions targeted by EWS-FLI are normally repressed and nucleosomal in primary endothelial cells. In tumor cells, however, bound regions are nucleosome-depleted and harbor the chromatin signature of enhancers. We next demonstrated that through chimerism, EWS-FLI acquired the ability to alter chromatin. Expression of EWS-FLI results in nucleosome depletion at targeted sites, whereas silencing of EWS-FLI in tumor cells restored nucleosome occupancy. Thus, the EWS-FLI chimera acquired chromatin-altering activity, leading to mistargeting, chromatin disruption, and ultimately transcriptional dysregulation. Examination of two transcription factors in two different cell types, as well as three histone methylation marks and FAIRE

2011-11-09 | E-GEOD-31838 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data